High-Definition Videobronchoscopy for the Diagnosis of Airway Involvement in Sarcoidosis: The Enhance Sarcoidosis Multicenter Study.
CT scan
endobronchial biopsy
endobronchial ultrasound
granuloma
high-definition videobronchoscopy
sarcoidosis
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
30
01
2023
revised:
07
04
2023
accepted:
23
04
2023
medline:
13
11
2023
pubmed:
1
5
2023
entrez:
30
4
2023
Statut:
ppublish
Résumé
The ability of high-definition (HD) videobronchoscopy to detect airway involvement in sarcoidosis has not been evaluated previously. What is the role of HD videobronchoscopy in the identification of sarcoidosis-associated airway abnormalities (AAs)? What are the patterns of AAs more commonly observed and more frequently associated with the detection of granulomas in endobronchial biopsy (EBB)? In this prospective international multicenter cohort study, consecutive patients with suspected sarcoidosis underwent airway inspection with an HD videobronchoscope and EBB using a standardized workflow. AAs were classified according to six patterns defined a priori: nodularity, cobblestoning, thickening, plaque, increased vascularity, and miscellaneous. We assessed diagnostic yield of EBB, prevalence of AAs, and interobserver agreement for different patterns of AAs. AAs were identified in 64 of 134 patients with sarcoidosis (47.8%), with nodularity (n = 23 [17.2%]), plaque (n = 19 [14.2%]), and increased vascularity (n = 19 [14.2%]) being the most prevalent. The diagnostic yield of EBB was 36.6%. AAs were significantly more prevalent in patients with than in those without nonnecrotizing granulomas on EBB (67.4% vs 36.5%; P = .001). Likewise, parenchymal disease on CT scan imaging was significantly more common in patients with than in those without nonnecrotizing granulomas on EBB (79.6% vs 54.1%; P = .003). On a per-lesion analysis, nonnecrotizing granulomas were seen especially in EBB samples obtained from areas of cobblestoning (9/10 [90%]) and nodularity (17/29 [58.6%]). The overall diagnostic yield of random EBB was low (31/134 [23.1%]). The interobserver agreement for the different patterns of AA was fair (Fleiss κ = 0.34). In a population with a large prevalence of White Europeans, HD videobronchoscopy detected AAs in approximately one-half of patients with sarcoidosis. The diagnostic yield of EBB was higher in patients with parenchymal involvement on CT scan imaging and in those with AAs, especially if manifesting as cobblestoning and nodularity. ClinicalTrials.gov; No.: NCT4743596; URL: www. gov.
Sections du résumé
BACKGROUND
The ability of high-definition (HD) videobronchoscopy to detect airway involvement in sarcoidosis has not been evaluated previously.
RESEARCH QUESTION
What is the role of HD videobronchoscopy in the identification of sarcoidosis-associated airway abnormalities (AAs)? What are the patterns of AAs more commonly observed and more frequently associated with the detection of granulomas in endobronchial biopsy (EBB)?
STUDY DESIGN AND METHODS
In this prospective international multicenter cohort study, consecutive patients with suspected sarcoidosis underwent airway inspection with an HD videobronchoscope and EBB using a standardized workflow. AAs were classified according to six patterns defined a priori: nodularity, cobblestoning, thickening, plaque, increased vascularity, and miscellaneous. We assessed diagnostic yield of EBB, prevalence of AAs, and interobserver agreement for different patterns of AAs.
RESULTS
AAs were identified in 64 of 134 patients with sarcoidosis (47.8%), with nodularity (n = 23 [17.2%]), plaque (n = 19 [14.2%]), and increased vascularity (n = 19 [14.2%]) being the most prevalent. The diagnostic yield of EBB was 36.6%. AAs were significantly more prevalent in patients with than in those without nonnecrotizing granulomas on EBB (67.4% vs 36.5%; P = .001). Likewise, parenchymal disease on CT scan imaging was significantly more common in patients with than in those without nonnecrotizing granulomas on EBB (79.6% vs 54.1%; P = .003). On a per-lesion analysis, nonnecrotizing granulomas were seen especially in EBB samples obtained from areas of cobblestoning (9/10 [90%]) and nodularity (17/29 [58.6%]). The overall diagnostic yield of random EBB was low (31/134 [23.1%]). The interobserver agreement for the different patterns of AA was fair (Fleiss κ = 0.34).
INTERPRETATION
In a population with a large prevalence of White Europeans, HD videobronchoscopy detected AAs in approximately one-half of patients with sarcoidosis. The diagnostic yield of EBB was higher in patients with parenchymal involvement on CT scan imaging and in those with AAs, especially if manifesting as cobblestoning and nodularity.
TRIAL REGISTRY
ClinicalTrials.gov; No.: NCT4743596; URL: www.
CLINICALTRIALS
gov.
Identifiants
pubmed: 37121391
pii: S0012-3692(23)00635-9
doi: 10.1016/j.chest.2023.04.034
pmc: PMC10635836
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT04743596']
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1243-1252Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
Ann Am Thorac Soc. 2015 Jan;12(1):85-90
pubmed: 25514623
Sarcoidosis Vasc Diffuse Lung Dis. 2001 Mar;18(1):91-2
pubmed: 11354554
Respiration. 2004 Jan-Feb;71(1):72-6
pubmed: 14872114
Respir Med. 2012 Jun;106(6):883-92
pubmed: 22417738
Ann Otol Rhinol Laryngol. 1981 Jul-Aug;90(4 Pt 1):339-43
pubmed: 7271144
Chest. 2001 Jul;120(1):109-14
pubmed: 11451824
Clin Rev Allergy Immunol. 2015 Aug;49(1):54-62
pubmed: 25779004
J Bronchology Interv Pulmonol. 2023 Oct 01;30(4):346-353
pubmed: 35959899
Monaldi Arch Chest Dis. 1999 Jun;54(3):217-23
pubmed: 10441973
Eur Respir J. 2010 Jun;35(6):1329-35
pubmed: 19897553
Chest. 2003 Dec;124(6):2126-30
pubmed: 14665490
Respir Med. 1991 May;85(3):229-34
pubmed: 1882112
Sarcoidosis Vasc Diffuse Lung Dis. 2004 Jun;21(2):147-51
pubmed: 15281436
J Bronchology Interv Pulmonol. 2017 Jan;24(1):48-58
pubmed: 27984385
Respirology. 2011 Apr;16(3):467-72
pubmed: 21261784
Chest. 1997 Mar;111(3):619-22
pubmed: 9118697
Respirology. 2015 Feb;20(2):226-34
pubmed: 25477156
Tohoku J Exp Med. 2011;223(2):119-23
pubmed: 21301185
BMJ Open Respir Res. 2018 May 18;5(1):e000295
pubmed: 29862031
Respirology. 2019 Jun;24(6):531-542
pubmed: 30912244
Respirology. 2022 Feb;27(2):152-160
pubmed: 34792268
Intern Med J. 2012 Apr;42(4):434-8
pubmed: 21299786
Clin Respir J. 2017 Jan;11(1):58-63
pubmed: 25919969
Turk Thorac J. 2016 Jan;17(1):22-27
pubmed: 29404117
Chest. 2014 Sep;146(3):547-556
pubmed: 24481031
Gastrointest Endosc. 2019 Feb;89(2):247-256.e4
pubmed: 30291849
Eur Respir J. 2018 Jan 25;51(1):
pubmed: 29371395
Curr Opin Pulm Med. 2003 Sep;9(5):402-7
pubmed: 12904711
J Bronchology Interv Pulmonol. 2014 Jul;21(3):220-6
pubmed: 24992130
J Bronchology Interv Pulmonol. 2017 Oct;24(4):315-318
pubmed: 28181962
Curr Opin Pulm Med. 2017 Sep;23(5):433-438
pubmed: 28590291
Lung. 2009 Jan-Feb;187(1):1-7
pubmed: 18716835
Eur Respir J. 2013 Nov;42(5):1302-8
pubmed: 23180586
J Thorac Cardiovasc Surg. 2012 Nov;144(5):1276-7; author reply 1277
pubmed: 23079018